Aspira Women's Health (Nasdaq: VRML) will release its second-quarter financial results for the period ending June 30, 2020, on August 13, 2020, after market close. A conference call and webcast will follow at 4:30 PM ET. Aspira focuses on innovative testing solutions for women's health, emphasizing ovarian cancer risk assessment and pelvic disease diagnostics. The company highlights its FDA-cleared product portfolio, including OVA1® plus and ASPIRA GenetiX™, while also developing new offerings like OVANEX™ and EndoCheck™.
Aspira Women’s Health Inc. (Nasdaq: VRML) announced a private placement agreement with investors, including affiliates of major stockholder Jack W. Schuler, to purchase approximately $11 million of unregistered shares at $3.50 each. The closing is expected on July 6, 2020, and gross proceeds will support sales, marketing, working capital, and strategic hires. Aspira specializes in gynecologic health and develops innovative testing solutions. The press release includes forward-looking statements subject to risks and uncertainties regarding market conditions and business performance.
Austin-based Vermillion, Inc. has rebranded as Aspira Women’s Health Inc., effective June 11, 2020. The company is now trading under the ticker symbol AWH on Nasdaq starting June 12, 2020. Aspira aims to be a leader in gynecologic health and has reported a 56% growth in its physician customer base, rising from 1,400 in 2018 to 2,700 in 2019. The company holds 85 filed and 40 pending patents, emphasizing its commitment to addressing women’s health issues, including ovarian cancer and endometriosis.
Vermillion, Inc. (Nasdaq: VRML) is set to join the Russell 3000 Index, effective June 29, 2020. This inclusion is expected to attract more interest from institutional investors, as Vermillion has shown progress in operational growth despite challenges from the COVID-19 pandemic. The Russell 3000 Index includes the 4,000 largest US stocks, and membership also grants entry into the large-cap or small-cap Russell indexes. This move could enhance Vermillion's visibility and investment potential in the market.
Vermillion, Inc. (Nasdaq: VRML) reported strong first-quarter results for 2020, with product revenue rising 55% to $1.2 million and test volume increasing 58% to 3,654 units, despite COVID-19 challenges. The company executed a preferred contract with Cigna, expanding its coverage to 16 million lives. Additionally, Vermillion received $1.0 million from the Paycheck Protection Program, which may be forgiven. The company remains optimistic about recovering test volumes and product pipeline growth post-pandemic.
Summary not available.